Form 4: SpringWorks Therapeutics Director Freda Lewis-Hall Reports Acquisition and Disposal of Shares

Director Freda Lewis-Hall reports acquisition of 10,060 shares and disposal of 24,727 shares of SpringWorks Therapeutics common stock on May 14, 2025, related to restricted stock units.

Summary

• On May 14, 2025, Freda Lewis-Hall, a director of SpringWorks Therapeutics, reported acquiring 10,060 shares of common stock.
• These shares were obtained through a grant of restricted stock units (RSUs) under the company's Amended and Restated Non-Employee Director Compensation Policy.
• The RSUs vest fully on the earlier of May 14, 2026, or the date of the next annual meeting of stockholders, contingent upon continued service.
• The director also disposed of 24,727 shares of common stock.
• Following these transactions, Lewis-Hall beneficially owns 24,727 shares of SpringWorks Therapeutics.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The transaction reflects standard compensation practices and insider alignment with shareholder interests.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Future Outlook

The director's continued service is tied to the vesting of the RSUs, suggesting an ongoing commitment to SpringWorks Therapeutics.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the ownership stake and activities of key personnel.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and ownership.

Key Dates

Keywords

SpringWorks Therapeutics, Director, Freda Lewis-Hall, RSU, Stock, Equity, Beneficial Ownership